The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Analysis of genomic alterations in matched circulating tumor cell DNA (CTC DNA) and plasma tumor DNA (ctDNA) in men with metastatic castration resistant prostate cancer (mCRPC).
 
Santosh Gupta
Research Funding - Bayer
 
Daniel H Hovelson
Travel, Accommodations, Expenses - Thermo Fisher Scientific
 
Scott A. Tomlins
Leadership - Strata Oncology
Stock and Other Ownership Interests - Strata Oncology
Consulting or Advisory Role - Abbvie; Almac Diagnostics; Astellas Medivation; Janssen; Sanofi; Strata Oncology
Research Funding - Astellas Medivation (Inst); GenomeDx (Inst)
Patents, Royalties, Other Intellectual Property - I am a coauthor on a patent issued to the University of Michigan on ETS gene fusions in prostate cancer. The diagnostic field of use has been licensed to Hologic/Gen-Probe Inc., who has sublicensed some rights to Ventana Medical Systems/Roche.
Travel, Accommodations, Expenses - Strata Oncology
 
Gabor Kemeny
No Relationships to Disclose
 
Chia-Jen Liu
No Relationships to Disclose
 
Daniel J. George
Honoraria - Axess Oncology; Bayer; BIOPHARM; Dendreon; Medivation; Novartis; Sanofi
Consulting or Advisory Role - Acceleron Pharma; Astellas Pharma; Bayer; Bristol-Myers Squibb; Celgene; Dendreon; Exelixis; Genentech; GlaxoSmithKline; Innocrin Pharma; Janssen; Medivation; Merck Sharp & Dohme; Myovant Sciences; Novartis; Pfizer; Sanofi
Speakers' Bureau - Bayer; Exelixis; Sanofi
Research Funding - Acerta Pharma (Inst); Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Exelixis (Inst); Genentech/Roche (Inst); Innocrin Pharma; Janssen Oncology (Inst); Millennium (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Bayer; Exelixis; Genentech/Roche; Medivation; Merck; Pfizer
 
Colin Rothwell
No Relationships to Disclose
 
Monika Anand
No Relationships to Disclose
 
David M. Nanus
Consulting or Advisory Role - Roche/Genentech
 
Paraskevi Giannakakou
Employment - Novartis (I)
Stock and Other Ownership Interests - Novartis (I)
Research Funding - Sanofi
Patents, Royalties, Other Intellectual Property - International Patent Application DOCKET NO. 1676.083WO1 “Identifying Taxane Sensitivity in Prostate Cancer Patients” (Giannakakou, Plymate, co-inventors)
 
Simon Gregory
Consulting or Advisory Role - Pfizer
Research Funding - Janssen (Inst)
 
Andrew J. Armstrong
Honoraria - Dendreon; Janssen Oncology; Sanofi
Consulting or Advisory Role - Bayer; Dendreon; Janssen Biotech; Medivation; Novartis; Pfizer; Sanofi
Speakers' Bureau - Bayer; Dendreon; Sanofi
Research Funding - Active Biotech (Inst); Astellas Pharma (Inst); Bayer (Inst); Dendreon (Inst); Gilead Sciences (Inst); Janssen Oncology (Inst); Medivation (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Circulating tumor cell novel capture technology (Inst)
Travel, Accommodations, Expenses - Bayer; Dendreon; Janssen Biotech; Medivation; Sanofi